Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis
Top Cited Papers
- 1 February 2007
- journal article
- research article
- Published by Elsevier BV in The Lancet
- Vol. 369 (9559), 381-388
- https://doi.org/10.1016/s0140-6736(07)60194-9
Abstract
No abstract availableKeywords
This publication has 42 references indexed in Scilit:
- Correction of Anemia with Epoetin Alfa in Chronic Kidney DiseaseThe New England Journal of Medicine, 2006
- Beware the meta-analysis — clozapine and suicidal ideationSchizophrenia Research, 2006
- Rationale—Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): Evolving the management of cardiovascular risk in patients with chronic kidney diseaseAmerican Heart Journal, 2005
- Anemia management for hemodialysis patients: Kidney Disease Outcomes Quality Initiative (K/DOQI) guidelines and Dialysis Outcomes and Practice Patterns Study (DOPPS) findingsAmerican Journal of Kidney Diseases, 2004
- Impact of epoetin alfa on clinical end points in patients with chronic renal failure: A meta-analysisKidney International, 2004
- Measuring inconsistency in meta-analysesBMJ, 2003
- Normalizing hematocrit in dialysis patients improves brain functionAmerican Journal of Kidney Diseases, 1999
- Coagulation Studies and Fistula Blood Flow During Erythropoietin Therapy in Haemodialysis PatientsNephrology Dialysis Transplantation, 1991
- Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. Canadian Erythropoietin Study Group.BMJ, 1990
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986